He revolutionised the human genome project. Now, Craig Venter is hoping to do the same for our understanding of the rest of the planet. Melissa Trudinger caught up with himon the Australian leg of his voyage of discovery on his yacht, Sorcerer II. [ + ]

Joe Sambrook tells Susan Williamson about the opportunities and challenges in understanding, treating and, ultimately, preventing breast cancer. [ + ]

Melissa Trudinger meets Richard Harvey, the recipient of the 2005 Julian Wells Medal. [ + ]

At 72, you'd think angiogenesis pioneer Judah Folkman would have the grace to slow down a little. Not so, finds Susan Williamson. [ + ]

Melissa Trudinger takes a candid look at the state of genomics research in Australia. [ + ]

Across the Australian research landscape, small genome projects are pushing their heads above the ground. [ + ]

Canada was one of the first countries to hop on the genomics bandwagon after the human genome project was completed. Since 2001, the Canadian federal government has invested C$386 million into Genome Canada, an independently operated organisation with the role of coordinating and funding genomics and proteomics research across Canada. [ + ]

Susan Williamson discovers why the theme of tissue architecture is so prominent at this year's Lorne Cancer conference. [ + ]

As with any emerging science there is some controversy regarding nomenclature, but the newly formed Metabolomics Society seems to be adhering to a convention consistent with the other '-omic' sciences

Are there some personalities that are better suited than others to a scientific career? To provide insight into this issue, The Science Advisory Board created the first-ever psychological profile of life science researchers

Vaxine's Nikolai Petrovsky says peptide vaccines work well in highly inbred laboratory mice, but have consistently failed in clinical trials over the past two decades because humans are an outbred species. [ + ]

Several Australian companies are trialling new 'natural' and synthetic adjuvants that combine potent immuno-stimulatory activity with low toxicity. Australia's biggest biotech, Melbourne's CSL (ASX:CSL), is boosting its experimental vaccines with its Iscomatrix adjuvant system, a phospholipid-cholesterol formulation containing a purified saponin extract from the bark of the South American tree Quillaja saponaria. [ + ]

Shakespeare's witches, in 'Macbeth', were concocting mischief, not some nostrum to ward off plague, but some of the things that imbue today's vaccines with immunogenic fizz would not have been misplaced among the eldritch ingredients in their cauldron. [ + ]

Some Australian biotechs are getting creative with company structure. But analysts prefer their companies to play it straight. [ + ]

In a recent project, electrophysiology researchers at Westmead Hospital in Sydney required a system to acquire and analyse signals measured using a micro-electrode array